UK MHRA Sets Out Regulatory Pathway for Microbiome-Based Medicinal Products
核心洞察
The UK MHRA published a position paper on 18 August 2026 clarifying that microbiome (搜索)-based medicinal products (MBMPs) fall within the existing Human Medicines Regulations 2012 framework.
No MBMP currently holds a UK marketing authorisation, though faecal microbiota transplantation remains available for recurrent Clostridioides difficile infection (搜索) via clinical trials and unlicensed "specials" routes.
The MHRA encourages early engagement through its Innovation Office and Scientific Advice services to clarify regulatory classification, align on CMC expectations, and de-risk development ahead of pivotal trials.
The Medicines and Healthcare products Regulatory Agency (搜索) (MHRA) has published a position paper clarifying how microbiome (搜索)-based medicines can be made available for patients in the UK, encouraging developers to pursue UK licensing pathways for this emerging class of therapies. Published on 18 August 2026, the paper confirms that microbiome-based medicinal products (MBMPs) fall within the scope of the existing UK medicines regulatory framework set out in the Human Medicines Regulations 2012, providing developers with a clear route to licensing while maintaining the same robust standards of quality, safety and efficacy that apply to all medicines in the UK.
MBMPs are medicines that work through modulating, restoring or replacing the human microbiome (搜索). They represent a promising new category of therapies with the potential to address areas of significant unmet clinical need such as antimicrobial resistance (搜索) (AMR). Depending on their characteristics, MBMPs may be regulated as biological medicinal products, or in some cases may meet the criteria for advanced therapy medicinal products (ATMPs).
Julian Beach, executive director of Healthcare Quality and Access at the MHRA, said: "Microbiome (搜索)-based medicinal products represent one of the most interesting and fast-moving areas in medicine today. Our position paper gives developers the clarity they need to bring these innovations forward with confidence, while ensuring patients continue to be protected by the same rigorous standards that underpin all licensed medicines in the UK."
Beach added: "The UK's existing, proportionate and evidence-based licensing frameworks are ready to support this field. Early engagement with us is the best way for developers to navigate it successfully."
Current Regulatory Landscape
As of July 2026, no MBMP has been granted a UK marketing authorisation. This contrasts with the US, where two donor-derived microbiota products have been licensed. Some countries have also authorised a small number of donor-derived microbiota products for Clostridioides difficile (C. difficile) infection. In principle, MBMPs may achieve marketing authorisation in the UK using the existing framework if developers can demonstrate appropriate standards of quality, safety and efficacy.
Despite the absence of authorised MBMPs, faecal microbiota transplantation (FMT) is available in the UK for specific indications, most notably recurrent C. difficile infection. FMT may be supplied within clinical trials where the investigational medicinal product has been manufactured under a manufacturing authorisation, as an unlicensed medicine operating under MHRA manufacturer's "specials" licences, or extemporaneously prepared in a pharmacy under section 10 of the 1968 Medicines Act. These routes remain under the direct responsibility of the prescribing clinician and are unaffected by the position paper publication.
The MHRA notes that the use of unlicensed medicines has enabled patient access and is designed to meet the needs of individual patients where no authorised medicines are available. However, the quality, safety and efficacy of unlicensed medicines have not been assessed by the MHRA.
Scientific and Regulatory Challenges
A central challenge for MBMP development is inherent variability, which complicates characterisation. Thorough characterisation is essential, as products may vary from fixed compositions to tailored microbial consortia, and composition may change during the product lifecycle. Characterisation studies are intended to identify Critical Quality Attributes (CQA) — the molecular and biological characteristics necessary to ensure consistency, safety and efficacy.
Many microbiome (搜索) products exhibit intrinsic biological variability, whether due to multi-strain composition, donor dependence, or dynamic behaviour during manufacture and storage. Developers must establish robust strategies for strain identification, potency assessment, control of batch-to-batch variability, and stability over the established shelf life. Current analytical tools, while advancing rapidly, may not be standardised or fully validated, but should be demonstrated to be suitable for their intended use.
Safety assessment of MBMPs requires particular attention to potential contamination with pathological microorganisms or toxins, risk of infection in vulnerable populations, and horizontal gene transfer — especially the potential transfer of antimicrobial resistance (搜索) (AMR) genes. The MHRA accepts the need for risk-based, product-specific safety strategies rather than reliance on conventional toxicology studies, which may be poorly predictive for microbiome (搜索)-modulating products.
Studies in animals may have limited relevance for predicting human effects due to species-specific microbiome (搜索) differences. The MHRA supports scientifically justified alternative approaches, including New Approach Methodologies (NAMs) and weight-of-evidence strategies, provided that uncertainties are transparently addressed.
Drug-Microbiota Interactions
Evidence suggests the microbiome (搜索) may be an important contributor to individual variability in drug responses and to adverse drug reactions. For example, gut microbiota may modulate cancer treatment responses to immune checkpoint inhibitors and chemotherapies. Similarly, differences in gut bacteria may alter responses to many commonly administered medications for cardiovascular disease, diabetes, Parkinson's disease, and other common diseases. Applicants should consider concomitant medication use during clinical development and the impact of MBMPs on pre-existing and new medical conditions.
International Context
The MHRA also notes ongoing developments internationally, including the EU's Substances of Human Origin (SoHO) Regulation, which explicitly includes intestinal microbiota and introduces a distinct regulatory framework for certain microbiome (搜索)-derived interventions within the EU from 2027. Under current legislation and the Windsor Framework, the SoHO regulation will apply in Northern Ireland, but not in Great Britain. UK Government consultation regarding SoHO regulation is currently in progress.
Early Engagement
Given the scientific novelty, regulatory complexity, and potential international divergence in expectations, the MHRA recommends early engagement. Innovation surgeries through the MHRA Innovation Office and scientific advice meetings allow developers to clarify applicable regulatory frameworks (for example, biological versus ATMP), agree proportionate non-clinical and clinical development strategies, align on CMC expectations including acceptable levels of variability, and de-risk development plans ahead of pivotal investment decisions.
The MHRA considers MBMPs acceptable in principle and capable of meeting UK regulatory standards for marketing authorisation. Progress toward licensure will depend on resolving challenges including product characterisation, CMC standardisation, safety (including antimicrobial resistance (搜索)), and clinical evidence generation. Early engagement with the MHRA remains the regulatory cornerstone for successful MBMP development in the UK.